Opko Health

Q2 FY2026 EarningsQ2 FY2026 revenue reached $163.5M, up 4.3% YoY, primarily driven by a 207% surge in IP and other revenue ($46.1M). Operating loss significantly narrowed to $7.0M from $60.0M YoY, benefiting from an $18.1M asset sale gain and reduced costs following the oncology unit divestiture. Net loss improved to $8.4M ($0.01 EPS) compared to $148.4M ($0.19 EPS) in the prior year. Cash and equivalents stood at $314.4M as of June 30, 2026.